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BRCA1 and BRCA2 mutations are responsible for most familial breast carcinomas. Recent reports carried out in 
non-cancerous mouse BRCA1- or BRCA2-deficient embryonic stem (ES) cells, and hamster BRCA2-deficient cells 
have demonstrated that the targeted inhibition of poly(ADP-ribose) polymerase (PARP-1) kills BRCA mutant 
cells with high specificity. Although these studies bring hope for BRCA mutation carriers, the effectiveness of 
PARP-1 inhibitors for breast cancer remains elusive. Here we present the first in vivo demonstration of PARP-1 
activity in BRCA1-deficient mammary tumors and describe the effects of PARP-1 inhibitors (AG14361, NU1025, 
and 3-aminobenzamide) on BRCA1-deficient ES cells, mouse and human breast cancer cells. AG14361 was 
highly selective for BRCA1-/- ES cells; however, NU1025 and 3-aminobenzamide were relatively non-selective. 
In allografts of naïve ES BRCA1-/- cells there was either partial or complete remission of tumors. However, in 
allografts of mouse, BRCA1-/- mammary tumors, there was no tumor regression or remission although a partial 
inhibition of tumor growth was observed in both the BRCA1-/- and BRCA1+/+ allografts. In human tumor cells, 
PARP-1 inhibitors showed no difference in vitro in limiting the growth of mammary tumors irrespective of their 
BRCA1 status. These results suggest that PARP-1 inhibitors may non-specifically inhibit the growth of 
mammary tumors. 
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1.  Introduction  
Germ line mutations of the breast cancer 
associated gene 1 (BRCA1) have been identified in 
about 50% of familial breast cancer cases and about 
90% of familial breast and ovarian cancers. 
Individuals who harbor a BRCA1 mutation have a 50 
to 80% lifetime risk of developing breast cancer by age 
70 [1]. Current screening and chemoprevention 
strategies are suboptimal and consequently some 
women who are BRCA1 gene carriers elect to 
prophylactically have their breasts and/or ovaries 
removed to reduce their cancer risk [2-4]. Moreover, 
current chemo-preventative drugs such as tamoxifen 
often have adverse effects, primarily due to poor 
specificity of these compounds to mammary tumor 
tissues [5]. Thus, there is an urgent need to develop 
safe and effective drugs for the chemoprevention and 
therapeutic treatment of breast cancer. Recently, two 
studies in Nature and another in Cancer Research, 
demonstrated that PARP-1 inhibitors kill BRCA 
deficient cells with extremely high efficiency while the 
BRCA+/- and BRCA+/+ cells are relatively non-
responsive to the treatment [6-8]. Thus, PARP-1 
inhibitors might be the long-sought genetically 
specific drug that is both safe and effective for 
BRCA1/2-associated breast cancers. These results 
received worldwide attention with commentaries in 
the press and multiple Journals [9]. Yet, these data 
were obtained by using non-cancerous and genetically 
naïve BRCA1/2-/- ES cells, BRCA2 conditional 
mutant mouse intestine, BRCA2-/- V-C8 hamster cells, 
and two BRCA2-proficient breast cancer cell lines, 
MCF7 and MAD-MB-231 that carried acute 
suppression of BRCA2 by siRNA. Breast cancers 
originated from targeted disruption of BRCA1/2, or 
naturally occurring BRCA1/2 mutations were not 
tested. Our previous studies on BRCA1-associated 
mouse models indicate that BRCA1 mutant tumors 
arise after multiple genetic alterations that allow cells 
to survive and grow, while ES cells with a 
homozygous BRCA1 mutation lack viability dying in 
utero [10]. In addition, the non-cancerous hamster cells 
have also been shown to be exquisitely labile and 
sensitive to insult [11-13]. These observations cast 
significant doubts on the effectiveness and specificity 
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application to BRCA1 associated breast cancer tumors.  
In order to have clinical relevance a more appropriate 
model should be used.  To investigate a potentially 
more clinically relevant model, we studied twelve cell 
lines, including BRCA1-deficient and wild type ES 
cells, transgenic and BRCA1 knock out mouse 
mammary tumor cell lines, as well as human 
BRCA1+/+, BRCA1+/-, and BRCA1-/- breast cancer 
cell lines with three PARP-1 inhibitors: the very potent 
PARP-1 inhibitor AG14361 (KI=5nM), a moderately 
potent PARP-1 inhibitor NU1025 (KI =50nM) and a 
weak PARP inhibitor 3-aminobenzamide (3AB) 
(KI=500nM) [14].  
2.  Materials and Methods 
Cells and Reagents 
MCF-7, HCC1937, and MDA-MB-231 cells were 
obtained from ATTC (Mannassas VA). SUM1315M02 
cells were obtained from Asterand (Detroit MI). The 
BRCA1 wild type and BRCA1 knockout mammary 
tumor cells were produced in this laboratory [10]. 
BRCA1+/- ES cells (24-28) were prepared as described 
previously, except that a hygmycin cassette was used 
instead of the neo g e n e  [ 1 5 ] .  T h e  B R C A 1 - / -  E S  c e l l s  
(24-27) were generated from the BRCA1+/- ES cells by 
deleting Brca1 exon 11 from the remaining Brca1 wild 
type allele using a conditional targeting vector 
described previously [[16] and data not shown]. 3-
Aminobenzamide was obtained from Sigma (St. Louis, 
MO). NU1025 was obtained from EMB biosciences (La 
Jolla, Calif.), and AG14361 (>99.9% pure) was 
prepared as previously described (Skalitsky et al.). 
Cells were grown in DMEM media with 10% fetal 
bovine serum in a 5% CO2 incubator in 37oC. Cells at 
80-85% confluence were trypsinized, washed with PBS 
and plated for each experiment. 
Clonogenic assays 
Three hundred ES cells, 500 mouse tumor cells or 
5000 human tumor cells were plated in 12 well costar 
flasks. After 18 hours, the cells were exposed to PARP-
1 inhibitor continuously, with changes in fresh media 
and PARP-1 inhibitor every four days. Colonies were 
grown for 10 days after which the colonies were fixed 
with methanol and stained with 1% Giemsa stain. 
Each experiment was performed in triplicate and each 
well counted three times 
MTT proliferation assays 
25,000 cells in the log phase of growth were 
plated in 12 well costar flasks. After 4 hours, PARP-1 
inhibitor was added and the cells were incubated for 
72 hours. The cells were then treated sequentially with 
1% thiazolyl blue tetrazolium for 20 minutes and 2-
propanol for 30 minutes. The absorption was read 
with the Perkin-Elmer 1420 multi-label counter. Each 
data point on each curve was replicated at least 8 
times. 
Tumor allograft studies 
500,000 cells were implanted subcutaneously 
bilaterally in the flanks and on the back of 6-8 weeks 
old female nude mice. There were five mice in each of 
the control groups and five mice in each of the 
treatment groups. Treatments were initiated when 
measurable tumors were present in all mice for the 
treatment studies or on the day after injection with 
tumor cells. In the treatment studies animals received 
either AG14361 at 30 mg/kg in vehicle (35% ethanol/ 
65% PBS) or vehicle alone intra-peritoneally for 5 days, 
or for three consecutive days every 5 days, all mice 
were monitored daily. For the tumor prevention 
studies, nude mice were injected intraperitoneally 
with either vehicle   AG14361 30 mg/kg one day prior 
to implantation bilaterally with 500,000 cells. The mice 
were treated based on different protocols described in 
the text. Mice were followed up to 19-21 days when 
largest tumor reached about 1.6 cm in the diameter. 
Tumor volume (V) was calculated as 
V=2/3p__X)__Y)_rZ). "r" is radius, and X, Y and Z 
refer to each axis. 
3.  Results  
Effects of PARP-1 inhibitors on mouse ES cells 
Our data on ES cells indicated that AG14361 is 
highly potent in killing BRCA1-/- cells in vitro and in 
vivo. The majority of BRCA1-/- ES cells were killed at 
a concentration of 0.01µM, and the surviving ES 
colonies had reduced size in the clonogenic assay (Fig. 
1A and not shown). No surviving colonies were 
observed at a concentration of 1 µM (Fig. 1A). The 
survival of BRCA1+/+ and BRCA1+/- (24-28) colonies 
was however also inhibited by AG14361 at higher 
concentrations though to a lesser degree than that the 
BRCA1-/- (24-27) cells (Fig. 1A). The ability of either 
NU1025 (Fig. 1B) or 3AB (Fig. 1C) to inhibit the 
survival of ES cells was less than that of AG14361 as 
measured through the clonogenic assay. Hence, 
although the most potent PARP-1 inhibitor (AG14361, 
KI =5nM) is highly specific to BRCA1-/- ES cells, the 
clonogenic assays suggested that the weaker PARP-1 
inhibitors (NU1025, KI =50nM; and 3AB, KI =500nM) 
are not. Next, the ability of AG14361 to inhibit the 
proliferation of ES cells as measured by MTT assay 
was evaluated (Fig. 1D). At levels of below 5 μM both 
the BRCA1-/- and BRCA1+/- ES cells were more 
sensitive to AG14361 growth inhibition than the wild 
type. 
We then evaluated the ability of AG14361 to 
prevent the development of ES tumors by treating the 
nude mice a day before implantation of ES cells with 
AG14361 and continuing for 9 days thereafter (Table 
1a). There was a 90% reduction in the formation of 
BRCA1-/- (24-27) ES derived tumors relative to the 
control. The only tumor developed in the BRCA1-/- 
tumor was also very small. There was however, only a 
22% reduction in the formation of BRCA1+/+ ES 
tumors. 
Next, we inoculated nude mice with ES cells and 
after the development of tumors treated the mice 
following an established procedure that efficiently 
killed BRCA2-/- V-C8 cells [7], ie. treatment of 
initiated tumors for five consecutive days with either Int. J. Biol. Sci. 2006, 2 
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vehicle or AG14361. The BRCA1-/- ES tumors 
underwent tumor regression in four out of the five 
mice treated with AG14361 (Table 1b). However, only 
one minor regression was seen out of the five mice 
with the BRCA1+/+ ES tumors. These results suggest 
that AG14361 is relatively specific in both preventing 
and treating BRCA1-/- ES tumors. 
Table 1  Response of embryonic stem cells to  AG14361 in  xenographs. a) Prevention of embryonic stem cell tumor 
formation in xenographs. b) Treatment of embryonic stem cell tumor formation in xenographs. 
 
CR, complete response, total regression of tumor, no tumor at autopsy; PR, partial response 50% reduction in tumor ; MR, minor response 25% reduction 
in tumor 
Figure 1. Response of ES cells to PARP-1 inhibitors. (A-C) Clonogenic survival assay of embryonic stem cells.  300 
colonies of ES (BRCA1+/+), 24-28 (BRCA1+/-) and 24-27 (BRCA1-/-) ES cells were plated followed 18 hours later with 
treatment by PARP-1 inhibitors: AG14361 (A), NU1025 (B) and 3-Aminobenzamide (C) for 10 days. (D) Response of ES 
cells to AG 14361 revealed by MTT assay. Filled circles ES colonies, open circles 24-28 colonies and filled triangles 24-27 
colonies.   
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Effects of PARP-1 inhibitors on mouse mammary tumor cells 
Thus our study, in principle, confirmed the previous finding that PARP-1 inhibitors could eliminate BRCA 
mutant cells both in vitro and in vivo. However, it remains unclear whether the PARP-1 inhibitors could prevent 
mammary cancer cell growth.  
Next, we evaluated the growth of mouse mammary tumor cells in the presence of AG14361, NU1025 or 
3AB. Five mouse mammary tumor cell lines were evaluated. This includes 3 cell lines derived from 
BRCA1Co/Co;MMTV-Cre  or BRCA1Co/Co;WAP-Cre mice carrying a Cre-loxP mediated deletion of BRCA1 exon 11 
(780 and 69) or complete deletion of BRCA1 (525), one cell line from MMTV-cNeu (NEU) and one line from 
MMTV-Ras (RAS) transgenic mice [10].  We have shown previously that many mammary tumors developed in 
BRCA1Co/Co;MMTV-Cre  or BRCA1Co/Co;WAP-Cre mice  had lost the entire BRCA1 coding region due to genetic 
instability in tumors (Figure No. 6 in Xu et al. 1999). The cell line 525 was derived from one of such tumors. Our 
data obtained from genomic PCR and RT-PCR confirmed the lack of BRCA1 coding region in this cell line (Fig. 
2A,B). There was no significant difference in the sensitivity to growth inhibition as measured by growth 
inhibition (GI50) by MTT assay to AG14361 among all three BRCA1 deficient cancer cell lines (referred as 
BRCA1-/- for simplicity), while the BRCA1 wild type cell lines (NEU and RAS) exhibited 1.5 to 11 fold decrease 
in sensitivity to AG14361 inhibition of growth compared with BRCA1 mutant cells (Fig. 2C).  
Figure 2. Treatment of mouse mammary tumors with PARP-1 inhibitors. (A, B), Genotyping of tumor cell lines 525 and 69 
using PCR (A) and RT-PCR (B) analysis. Primers used for PCR are Brca1, 5’ CTG GGT AGT TTG TAA GCA TCC 3’ and 
5’ CTG CGA GCA GTC TTC AGA AAG 3’ which amplify 621 bp from mutant allele after Cre-loxP mediated deletion; 
Smad4, 5’-GGG CAG CGT AGC ATA TAA GA -3’ and 5’-GAC CCA AAC GTC ACC TTC AC -3’ which amplify about 
450 bp as a control for DNA. Primers used for RT-PCR are Brca1, 5’ CTC AAG AAG CTG GAG ATG AAG G 3’ and 5’ 
GAA GAT GCC TAG AGC AGC CAT G 3’ which amplify about 540 bp from Brca1 transcripts encoding BRCA1 short 
isoform; Gapdh, 5’ ACA GCC GCA TCT TCT TGT GC 3’ and 5’ TTT GAT GTT AGT GGG GTC TCG C 3’ which 
amplify about 450 bp as a control for RT-PCR. (C-E) MTT proliferation assay: BRCA1 wild type (NEU and RAS) and 
BRCA1-/- (780
,  69, and 525) mouse mammary tumor cells were treated with AG14361 (C), NU1025 (D), and 3-
Aminobenzamide (E) for 72 hours respectively. (F) Clonogenic survival assay. Five hundred 780, NEU, and 525 cells were 
exposed to AG14361 each for 10 consecutive days, 18 hours after plating.  
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Next, the ability of NU1025 to inhibit these tumor lines was evaluated. NU1025 was only minimally more 
selective for the BRCA1-/- cell lines at levels below 1 µM of NU1025 Again the observed selectivity disappeared 
at about 10µM (Fig. 2D). The inhibitory ability of NU1025 was less than that observed for the stronger PARP-1 
inhibitor AG14361 (Fig 2C). The weak PARP-1 inhibitor 3AB was less able to inhibit tumor cell proliferation in 
vitro than either AG14361 or NU1025 though 3AB also was more selective towards BRCA-/- cells at lower 
concentrations (Fig. 2E). Thus at low concentrations of PARP-1 inhibitors, their was some minimal to mild 
selectivity towards the inhibition of growth for BRCA1 knock out tumor cells, this difference however was not 
found at higher concentrations of PARP-1 inhibitors. We next performed clonogenic assays of the NEU, 780 and 
525 cell lines, where we found that the BRCA1-/- tumor cells (780 and 525) were much more sensitive to 
AG14361 treatment than BRCA1+/+ tumor cells (NEU) (Fig. 2F). At concentrations of AG14361 of 0.1 and 1 μM, 
there was about 8-fold difference in survival rate. This difference, however, is much lower compared with an 
over 100 fold difference reported previously on pre-cancerous cells [6, 7]. 
The in vitro experiments were followed by in vivo examination of BRCA1+/+ and BRCA1-/- mammary 
tumors exposed to 5 days of high dose AG14361 treatment. Inhibition of mammary tumor growth was observed 
two days after the fifth AG14361 injection relative to the control in both wild type and mutant cell lines (Fig. 
3A,B). There were however no complete remissions, or partial remissions observed. Next, we followed a 
prevention protocol that was used to successfully eliminate sensitivity of BRCA-/- ES cell derived tumors to 
PARP-1 inhibitors [6]. However, our data indicated that the treatment failed to achieve a more than marginal 
specific killing of BRCA1 mutant cancer cells as both BRCA1-/- and BRCA1+/+ cells showed about a 30-40% 
reduction in growth (Fig. 3C,D). These observations revealed a significant difference between BRCA1 mutant ES 
cells and cancer cells in their response to PARP-1 inhibitors. 
Figure 3. Response of in vivo allograft of BRCA1+/+ and BRCA1-/- mammary tumor cells to AG14361. Treatment intra-
peritoneally with AG14361 (30 mg/kg) for five consecutive days as indicated by the arrows (days 5-9 after implantation) (A, 
B), or for three consecutive days starting on days 2, 9 and 16 (C, D). The mice were monitored daily. The average tumor 
size is indicated above for all five mice in both the control and treatment groups. 
 
Effects of PARP-1 inhibitors on human breast cancer cells 
Evaluation of human mammary tumor cells followed. Four cell lines derived from human breast cancers, 
MCF-7 (BRCA1+/+ and ERα+), MDA-MB-231 (BRCA1+/-, ERα-), HCC1937 (BRCA1-/-, ERα-) and 
SUM1315MO2 (BRCA1-/-, ERα
−), were evaluated through their response to PARP-1 inhibitors. AG14361 
showed little to no specificity in inhibiting the MDA-MB-231, HCC1937 or SUM1315MO2 cells as compared to Int. J. Biol. Sci. 2006, 2 
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its inhibition of MCF-7 cells (Fig. 4A). It is noted that the HCC1937 (5382insC) and the SUM1315MO2 
(185delMO2) carry mutations of the BRCA1 genes that account for 85% of the human BRCA1 associated breast 
cancers [17]. The HCC1937 cells were slightly more sensitive to growth inhibition by NU1025 than MCF-7 cells 
(Fig. 4B). This was a bit surprising as NU1025 is less potent than AG14361. Next the ability of 3AB to inhibit 
breast cancer growth was evaluated. At concentrations below approximately 7-8 µM, 3-AB was slightly more 
effective in inhibiting the growth of HCC1937 and MDA-MB-436 cells as opposed to MCF-7 cells. This difference 
disappeared at higher doses (Fig. 4C). We next performed clonogenic assays and found that the survival fraction 
of both MDA-MB-231 and HCC1937 were slightly less that of MCF-7 above 1 µM (Fig. 4D). 
Thus, our studies indicate that the use of PARP-1 inhibitors in mouse BRCA1-/- mammary cancer cells 
seems to show only mild specificity in comparison with their controls, while PARP-1 inhibitors seem to 
uniformly inhibit growth of human breast cell lines regardless of the BRCA1 genotypes.  
Figure 4.  Response of human mammary tumors to treatment with PARP-1 inhibitors.  (A-C) MTT assay: 25000 MCF-7 
(BRCA1+/+), MDA-MB-231 (BRCA1+/-), HCC1937 (BRCA1-/-), and SUM1315MO2 (BRCA1-/-) human breast cancer 
cells were treated for 48 hours with AG14361 (A), NU1025 (B) and/or 3-Aminobenzamide (C), respectively. (D) 
Clonogenic assay: MCF-7, MDA-MB-231 and HCC1937 cells were treated and exposed to AG14361 continuously for 10 
days.  
 
4.  Discussion 
We have shown that the PARP-1 inhibitor AG14361 selectively kill BRCA1-/- ES cells with high efficiency 
while it does not preferentially kill BRCA1-/- breast cancer cells compared with BRCA1+/+ controls. By 
definition a tumor cell represents a cell that has had multiple genetic mutations and that in tumor there may be 
numerous fundamentally different cancer cells when classified strictly by the type and frequency of individual 
genomic changes [10, 18, 19]. Thus, caution needs to be made in interpreting findings from BRCA1-/- ES cells, 
which have not gone through these genetic changes.  
In addition, we found that the MTT assay is a more consistent model in predicting the sensitivity and 
specificity of tumor cells to PARP-1 inhibitors in comparison with profiles of tumor progression obtained from 
allograft models as opposed to the clonogenic assay. The higher sensitivity observed in clonogenic assay may be 
in part due to the extraordinary constant exposure to high drug concentrations, which would  likely not be 
possible for such a length of time in any therapeutic treatment of human or in vivo animal systems. In addition, 
cancer cells are exquisitely dependant to other cancer cells for survival and growth in vivo and in vitro through 
paracrine cell/cell interactions. The low inoculating cell density in clonogenic assay may also be a factor for the 
increase sensitivity for the drug treatment. Int. J. Biol. Sci. 2006, 2 
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Notably, we found that PARP-1 inhibitors can inhibit breast cancer cells irrespective of their BRCA1 and 
ERα status. This might potentially have significant clinical importance, as most BRCA1-/- breast cancers are 
ERα negative and thus do not exhibit a response to hormonal treatment such as tamoxifen [20, 21]. The use of 
PARP-1 inhibitors in combination with standard chemotherapy regiments may also prove to be a worthwhile 
endeavor as one can conceive of having to give only lower levels of PARP-1 inhibitors in combination with other 
drugs than alone in the treatment of breast cancers. 
While this study tested effects of PARP-1 inhibitors on BRCA1 mutant cells, it is worthwhile to note that a 
recent investigation revealed no specific cell killing was found in pancreatic BRCA2-deficient human cancer, 
CAPAN-1, cells by NU1025 or 3AB [22], which is in a strong contrast to the results showing that NU1025 kills 
the non-cancerous hamster BRCA2-/- cells with high efficiency and specificity [7]. This was attributed to the 
weak activity of NU1025, as these cells can be efficiently killed by KU0058684 and KU0058948, which are more 
potent PARP-1 inhibitors [23]. Yet, clinically speaking as implied by Gallmeier and Kern [22], it is not the 
potency of a drug that is most important but the efficacy. That is the maximum biological effect, is perhaps the 
most important criteria by which clinicians treat patients. In addition, though we have shown that PARP-1 
inhibitors are only minimally selective, if at all, to BRCA1-/- mammary tumors, our preliminary observation 
indicates that PARP-1 inhibitors may be useful in combination with standard chemotherapy in treating breast 
cancer (Our unpublished observation). We are now in the process of investigating combination therapy with 
AG14361, which is as at least as potent as KU0058684 and KU0058948, to test whether PARP-1 inhibitors can 
specifically/synergistically kill BRCA1/2-/- breast cancer cells with selective chemotherapeutic agents. 
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